OSAM
NBIX icon

O'Shaughnessy Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

O'Shaughnessy Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$654K Sell
4,964
-177
-3% -$23.5K ﹤0.01% 1398
2025
Q4 		$729K Buy
5,141
+546
+12% +$79.1K ﹤0.01% 1303
2025
Q3 		$645K Sell
4,595
-234
-5% -$31.7K ﹤0.01% 1361
2025
Q2 		$607K Buy
4,829
+1,599
+50% +$183K ﹤0.01% 1281
2025
Q1 		$357K Sell
3,230
-543
-14% -$68.8K ﹤0.01% 1482
2024
Q4 		$515K Sell
3,773
-36
-0.9% -$4.45K ﹤0.01% 1272
2024
Q3 		$444K Sell
3,809
-461
-11% -$63.2K ﹤0.01% 1285
2024
Q2 		$588K Buy
4,270
+575
+16% +$78.9K 0.01% 1063
2024
Q1 		$510K Buy
3,695
+531
+17% +$72.5K 0.01% 1093
2023
Q4 		$417K Buy
3,164
+109
+4% +$12.5K 0.01% 1084
2023
Q3 		$344K Buy
+3,055
New +$322K 0.01% 1054
2023
Q2 		– Sell
-2,366
Closed -$239K – 1553
2023
Q1 		$239K Sell
2,366
-543
-19% -$56.5K ﹤0.01% 1142
2022
Q4 		$347K Buy
2,909
+365
+14% +$42.8K 0.01% 917
2022
Q3 		$270K Buy
+2,544
New +$258K 0.01% 976
2021
Q4 		– Sell
-1,224
Closed -$118K – 2018
2021
Q3 		$118K Sell
1,224
-1,077
-47% -$102K ﹤0.01% 1304
2021
Q2 		$224K Buy
2,301
+37
+2% +$3.55K ﹤0.01% 973
2021
Q1 		$220K Sell
2,264
-259
-10% -$27.2K ﹤0.01% 891
2020
Q4 		$242K Buy
2,523
+738
+41% +$71.3K 0.01% 765
2020
Q3 		$172K Buy
1,785
+570
+47% +$65.9K 0.01% 747
2020
Q2 		$148K Buy
+1,215
New +$134K ﹤0.01% 740
2020
Q1 		– Sell
-23
Closed -$2K – 1618
2019
Q4 		$2K Buy
+23
New +$2.41K ﹤0.01% 1664

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

O'Shaughnessy Asset Management's NBIX Position: Q1 2026 in Review

O'Shaughnessy Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 3.4% in Q1 2026, selling an estimated $23.5K and leaving 4,964 shares worth $654K. The position accounts for ﹤0.01% of the portfolio, ranked #1398.

O'Shaughnessy Asset Management first reported a position in NBIX in Q4 2019 and has held it in 21 quarters since. The position peaked at $729K in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • O'Shaughnessy Asset Management held 4,964 shares of Neurocrine Biosciences worth $654K as of Q1 2026.
  • O'Shaughnessy Asset Management sold 177 Neurocrine Biosciences shares in Q1 2026, an estimated $23.5K.
  • Neurocrine Biosciences made up ﹤0.01% of O'Shaughnessy Asset Management's portfolio in Q1 2026, its #1398 holding.
  • O'Shaughnessy Asset Management first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 21 quarters since.
  • O'Shaughnessy Asset Management's Neurocrine Biosciences position peaked at $729K in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on O'Shaughnessy Asset Management's 13F filing for Q1 2026, filed 13 May 2026.